Clinical Analysis of Autologous Cytokine-induced Killer Cells Combined with IL-2 for Treating of Elderly Patients with B-cell Malignant Lymphoma.

Yi WU; Lin SHI; Lei FENG; Dian-Liang LV

Return

Clinical Analysis of Autologous Cytokine-induced Killer Cells Combined with IL-2 for Treating of Elderly Patients with B-cell Malignant Lymphoma.

Author: Yi WU ¹ ; Lin SHI ² ; Lei FENG ¹ ; Dian-Liang LV ¹
Author Information

1. Department of Hematology, Traditional Chinese Medicine Hospital of Henan Province, Zhengzhou 450002, Henan Province, China.
2. Department of Hematology, Traditional Chinese Medicine Hospital of Henan Province, Zhengzhou 450002, Henan Province, China. E-mail: slin7085@163.com.
Publication Type:Journal Article
MeSH: Aged; Cytokine-Induced Killer Cells; cytology; Humans; Interleukin-2; therapeutic use; Lymphoma, Large B-Cell, Diffuse; therapy; Quality of Life; Recombinant Proteins; therapeutic use; T-Lymphocyte Subsets
From: Journal of Experimental Hematology 2016;24(3):738-743
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo explore the values of autologous cytokine-induced killer cells combined with rhIL-2 for therapy of elderly patients with B-cell malignant lymphoma.
METHODSEighty-five elderly patients with B-cell malignant lymphoma were treated by cytokine induced killer cells combine with rhIL-2 (CIK+IL-2 group), 85 elderly patients with B-cell malignant lymphoma treated without cytokine induced killer cells combined with rhIL-2 were used as the control group. The patients in CIK+IL-2 group and control group were divided into 4 subgroups accerding to lymphoma types: group A: diffuse large B cell lymphoma (DLBCL), group B: mucosa-associated lymphoid tissue type (MALT), group C: lymphoplas macytic lymphoma (LPL) and group D: hodgkin's lymphma (HL). The clinical effects, T-lymphocyte, β2 microglobulin level, quality of life and long-term survival were observed.
RESULTSThe levels of CD3+, CD3+/CD8+, CD3+/CD56+ after treatment in the 4 subgroups of CIK+IL-2 group were higher than levels before treatment and the control group (P<0.05); the levels of β2 microglobulin after treatment for the 4 groups were lower than before treatment and the control group (P<0.05); with 1 case death, 16 cases were turned from CRu and PR to CR; the CR rate was not significantly different among the 4 subgroups (P>0.05); the scores of physical performance, role function, cognitive function, emotional functioning, and social function after treatment in the 4 subgroups were higher than the those before treatment (P<0.05); the survival time of patients in the CIK+IL-2 group lasted for 8-76 months, their median survival time was (22.36±5.38) months; the survival of the control group lasted for 7-55 months, their median survival time was (16.15±3.62) months. The survival time of the CIK+IL-2 group was longer than that of the control group (P<0.05).
CONCLUSIONThe treatment of aged patients with B-cell malignant lymphoma by autologous cytokine-induced killer cells combined with rhIL-2 can effectively improve the T-lymphocyte subsets, β2 microglobulin level and quality of life, and can prolong survival time of patients.